Release date: 2017-02-07
         
Researchers at the Heddes Sinai Medical Center recently published a new study in the international academic journal NEJM. They found that in patients with prostate cancer who had been removed from the prostate, the addition of hormone therapy during radiotherapy significantly prolonged the patient's Average survival time. The study also found that this strategy can reduce the probability of cancer spread.
Prostate cancer is the second most common cancer in American men. According to estimates by the American Cancer Society, there will be approximately 16,300 new cases of prostate cancer in 2017, and 27,000 people will die from the disease.
"Our research shows that hormonal therapy can be added to patients who need radiation therapy after surgery," said Dr. Howard Sandler, senior author of the study. He also said that more than 30% of prostate cancer patients will have a recurrence of disease within one to four years after surgical removal of the prostate. When the patient has recurrence symptoms, the doctor usually performs radiation therapy on the patient. The results of this study indicate that the addition of hormone therapy during radiotherapy can prolong the patient's life.
The study included researchers from 17 medical research units. A total of 761 patients participated in randomized clinical trials using combination therapies between 1998 and 2003. The researchers followed these patients for up to 12 years.
The main findings of the study include:
After 12 years, the mortality rate of prostate cancer patients receiving combined therapy was 5.4%, while that of prostate cancer patients receiving only radiation therapy was 13.4%.
14.5% of patients with prostate cancer who received combination therapy had metastases, and 23% of patients with prostate cancer who received radiation therapy.
The side effects of the two groups of patients were mild and similar. The hormone therapy used in this study is mainly used to inhibit androgen, which stimulates the growth of prostate cancer cells. Participants in the clinical trial took the drug every day for two years, Sandler said they later replaced the previously used bicalutamide with a GnRH agonist, both of which inhibit hormone synthesis, suggesting that hormone therapy combined with radiation therapy can significantly reduce the prostate. Metastatic risk and mortality in cancer patients.
Sandler also pointed out that future research needs to continue to explore whether all prostate cancer patients need hormone therapy to further determine the duration of treatment and the role of more powerful hormone therapy.
Source: Bio Valley
Household Gloves,Gloves Microfiber,Flock Lined Glove,Household Latex Work Glove
ZHANGJIAGANG DINSHENGLIN TRADING CO.,LTD , https://www.dslhouse.com